IP Verse

Methods Of Reducing The Risk Of Cardiovascular Events In A Subject - EP4056176

The patent EP4056176 was granted to Amarin Pharmaceuticals Ireland on Apr 24, 2024. The application was originally filed on Apr 22, 2019 under application number EP22171033A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4056176

AMARIN PHARMACEUTICALS IRELAND
Application Number
EP22171033A
Filing Date
Apr 22, 2019
Status
Granted And Under Opposition
Mar 22, 2024
Grant Date
Apr 24, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELKINGTON AND FIFEJan 24, 2025ELKINGTON AND FIFEADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONUS2007185198
OPPOSITIONUS2010311834
OPPOSITIONUS2018153846
SEARCHUS2007185198
SEARCHUS2010311834
SEARCHUS2018153846

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- MARTIN SSBLAHA MJELSHAZLY MB et al., "Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile", JAMA, (20130000), vol. 310, pages 2061 - 8-
DESCRIPTION- RONDEAU V., "Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events", Biostatistics, (20070000), vol. 8, pages 708 - 21-
OPPOSITION- Anonymous, "High Blood Cholesterol What you need to know", US Department of Health and Human Services, (20050101), pages 1 - 6, XP093258740-
OPPOSITION- Anonymous, "ICH Harmonised Tripartite Guidelines: Structure and Content of Clinical Trial Reports E3", INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, (19951130), pages 1 - 49, XP093258782-
OPPOSITION- Anonymous, " Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95)", EMEA, (20220701), pages 1 - 48, XP093258775-
OPPOSITION- D09: Summary of Product Characteristics, Vazkepa, 2021-
OPPOSITION- D10a: Highlights of Prescribing Information, LOVAZA, 2012-
OPPOSITION- D10b: Highlights of Prescribing Information, LOVAZA, 2008-
OPPOSITION- D11: Highlights of Prescribing Information, Vascepa, 2012-
OPPOSITION- D13: Amarin’s AMR101 phase 3 ANCHOR trial meets all primary and secondary endpoints with statistically significant reductions in triglycerides at both 4 gram and two gram doses and statistically significant decrease in LDL-C, Press Release dated 8 April 2011-
OPPOSITION- Kowey Peter R. et al, "Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation A Randomized Controlled Trial", JAMA, (20101201), vol. 304, no. 21, pages 2363 - 2372, XP093258746-
OPPOSITION- Matsuzaki M., Et Al., "Incremental Effects of Eicosapentaenoic Acid on Cardiovascular Events in Statin-Treated Patients With Coronary Artery Disease - Secondary Prevention Analysis From JELIS", Circ J, (20090101), vol. 73, pages 1283 - 1290, XP055844740-
OPPOSITION- Bhatt Deepak L. et al, ": Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial", Clinical Cardiology (Hoboken), John Wiley & Sons, Inc., US, US , (20170301), vol. 40, no. 3, doi:10.1002/clc.22692, ISSN 0160-9289, pages 138 - 148, XP093091478
OPPOSITION- Beatriz G. Talayero; Frank M. Sacks, "The Role of Triglycerides in Atherosclerosis", Current Cardiology Reports, Current Science Inc., New York, New York , (20111004), vol. 13, no. 6, doi:10.1007/s11886-011-0220-3, ISSN 1534-3170, pages 544 - 552, XP019972113
OPPOSITION- Harold E. Bays et al, "Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)", AMERICAN JOURNAL OF CARDIOLOGY., CAHNERS PUBLISHING CO., NEWTON, MA,, US, US , (20110424), vol. 108, no. 5, doi:10.1016/j.amjcard.2011.04.015, ISSN 0002-9149, pages 682 - 690, XP028262633
OPPOSITION- Christie M. Ballantyne et al, "Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)", AMERICAN JOURNAL OF CARDIOLOGY., CAHNERS PUBLISHING CO., NEWTON, MA,, US, US , (20121001), vol. 110, no. 7, doi:10.1016/j.amjcard.2012.05.031, ISSN 0002-9149, pages 984 - 992, XP055196958
OPPOSITION- Christie M. Ballantyne et al, "Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies", Atherosclerosis, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20160820), vol. 253, doi:10.1016/j.atherosclerosis.2016.08.005, ISSN 0021-9150, pages 81 - 87, XP055743795
OPPOSITION- Bhatt Deepak L. et al, "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia", The New England journal of medicine, Massachusetts Medical Society, US, US , (20190103), vol. 380, no. 1, doi:10.1056/NEJMoa1812792, ISSN 0028-4793, pages 11 - 22, XP093246167
OPPOSITION- Eliot A. Brinton, R. Preston Mason, "Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)", Lipids in Health and Disease, (20171201), vol. 16, no. 1, doi:10.1186/s12944-017-0415-8, XP055743790
SEARCH- CHRISTIE M. BALLANTYNE ET AL, "Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)", AMERICAN JOURNAL OF CARDIOLOGY., US, (20121001), vol. 110, no. 7, doi:10.1016/j.amjcard.2012.05.031, ISSN 0002-9149, pages 984 - 992, XP055196958 [Y] 1-5 * page 987; table 1 * * page 988, column r, paragraph 2 * * page 991, column r, paragraph 1 * * abstract *
SEARCH- CHRISTIE M. BALLANTYNE ET AL, "Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies", ATHEROSCLEROSIS, AMSTERDAM, NL, (20160820), vol. 253, doi:10.1016/j.atherosclerosis.2016.08.005, ISSN 0021-9150, pages 81 - 87, XP055743795 [Y] 1-5 * page 83, column r, paragraph 2 - page 84, column r, paragraph 1 * * abstract *
SEARCH- Deepak L Bhatt, "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia", doi:10.1056/NEJMoa1812792, (20190103), URL: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1812792?articleTools=true, (20200303), XP055673350 [PX] 1-5 * the whole document *
SEARCH- ELIOT A. BRINTON ET AL, "Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)", LIPIDS IN HEALTH AND DISEASE, (20170131), vol. 16, no. 1, doi:10.1186/s12944-017-0415-8, XP055743790 [Y] 1-5 * page 8, column r, paragraph 2 - page 10 *
SEARCH- MATSUZAKI, "Incremental Effects of Eicosapentaenoic Acid on Cardiovascular Events in Statin-Treated Patients With Coronary Artery Disease.", CIRCULATION JOURNAL, (20090101), vol. 73, doi:10.1253/circj.CJ-08-1197, pages 1283 - 1290, XP055181321 [Y] 1-5 * page 1284, column l, paragraph 3 * * page 1288, column 2, paragraph 2 * * page 1289, column l, paragraph 3 * * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents